Background: As costs of cancer care rise, the importance of documenting value in oncology increases. Proton beam radiotherapy (PBT) has the potential to reduce toxicities in cancer patients, but is relatively expensive and unproven. Evaluating quality of life (QOL) and patient-reported outcomes (PROs) is essential to establishing PBT's "value" in oncologic therapy. The goal of this systematic review was to assess QOL and PROs in patients treated with PBT. Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic searches were conducted. The PubMed search engine was the primary data source, along with publications found from references of selected articles, and articles known to the authors published through 2017. Seventeen original investigations were found to have sufficient focus and relevance to be incorporated into the systematic review. Results: Studies of skull base (n ¼ 1), brain (n ¼ 1), head/neck (n ¼ 1), lung (n ¼ 1), breast (n ¼ 2), prostate (n ¼ 8), and pediatric (n ¼ 3) malignancies treated with PBT that met eligibility criteria were included. QOL did not deteriorate during PBT for skull base and after PBT for brain tumors, respectively. PROs were higher for PBT than photon-based radiotherapy for both head/ neck and lung cancer. Patient-reported breast cosmesis was appropriate after PBT and comparable to photon modalities. PBT in various settings of prostate cancer displayed an expected post-therapy decline; one study showed improved PROs (rectal urgency, bowel frequency) for PBT, and two others showed PROs/QOL comparable with other modalities. Pediatric studies demonstrated improvements in QOL during therapy, with additional increases thereafter. Conclusions: Based on limited data, PBT provides favorable QOL/PRO profiles for select brain, head/neck, lung, and pediatric cancers; measures for prostate and breast cancers were more modest. These results have implications for cost-effective cancer care and prudently designed QOL evaluation in ongoing trials, which are discussed. Future data could substantially change the conclusions of this review.
Although most CE analyses focus on direct healthcare costs, long-term QOL declines can lead to a substantial increase in indirect costs that are due to treatment morbidity (4) . As a result, it is becoming essential to carefully analyze subjective measures such as QOL when evaluating the comparative effectiveness of new treatment approaches.
QOL is an inherently multidimensional concept that is dependent on various perspectives, and without a unified definition (5, 6) . Several validated QOL and PRO questionnaires are used in oncologic clinical research. QOL measures, such as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ) and the Pediatric QOL Questionnaire (PedsQoL), evaluate functional, symptomatic, and psychosocial elements of cancer therapy, along with more disease-focused measures and a composite global parameter. PROs, which are more tailored toward symptoms, can be general and/or entirely disease specific, such as the MD Anderson Symptom Inventory (MDASI), Harvard Breast Cosmesis Scale, Expanded Prostate Cancer Index Composite (EPIC), and Prostate Cancer Symptom Index (PCSI). Both types of questionnaires are usually administered before therapy and at various subsequent intervals during or after treatment.
QOL and PROs are especially relevant to oncology given the unprecedented proliferation of surgical innovations, biologic therapies, and radiation therapy (RT) technologies. A prime example of these radiation technologies is proton beam therapy (PBT), which has grown exponentially worldwide over the present decade and is likely to continue at an even greater pace in the near future (7). The dosimetric advantages of PBT over intensity-modulated RT (IMRT) and 3D-conformal RT (3DCRT) have been buoyed by emerging clinical data demonstrating PBT to be a safe and effective option to treat many neoplasms (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . The promise of PBT has been primarily attributed to potential toxicity reductions and attenuation of post-treatment QOL decline. However, proton facilities are expensive and do not yet have mature phase III data to support routine utilization (23) . The result has been a sometimes intense debate about the use of PBT in a VBO system (24) .
A major challenge in analyzing the CE of PBT is the lack of comprehensive evaluations of QOL/PRO results for PBT. Indeed, the majority of economic studies, which use the primary measure of cost per quality-adjusted life-year, do not actually account for QOL (25) . In addition, critical assessment of existing QOL data is a main prerequisite for well-designed evaluation of QOL in ongoing trials. This systematic review focusing on QOL and PROs in patients treated with PBT is intended to address this need. We critically appraise available QOL/PRO evidence, relate the findings to CE and VBO, and identify current knowledge gaps.
Methods
This systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (26) . Eligibility criteria included published work in English evaluating QOL and/or PROs during and/or following proton RT. The PubMed search engine was the primary data source, along with publications found from references of selected articles and articles known to the authors. Unpublished abstracts were not included because of the inability to completely assess validity and methodologies. Searches were intended to identify all articles addressing this subject with the following search terms: proton, proton therapy, proton radiation therapy, proton beam therapy, quality of life, QOL, and patient-reported outcomes. Care was taken to ensure that the inclusion criteria were sufficiently broad so that possibly pertinent publications could be assessed by individual screening rather than being excluded by the initial search. Systematic searches, conducted by all authors, did not utilize date restrictions and included articles published through March 2017. It was not possible to perform a meta-analysis on the available literature because of the inherent heterogeneity in study designs, scale, and characteristics.
Based on the initial searches, a total of 223 articles were identified ( Figure 1 ). Several journal publications were from the same group of researchers and analyzed overlapping patient populations. In such instances, the prioritized publication had a higher sample size, was more recent, and/or performed a broader spectrum of QOL/PRO analyses. An exception was made for two studies evaluating QOL/PROs while stratifying for a salient clinical variable (eg, history of a procedure that could impact QOL/PROs) that had been unreported in a prior analysis. After duplicates were removed, each of the 216 remaining eligible items was independently screened for the inclusion criteria, and a further 193 were determined to be ineligible. Articles were excluded for several reasons, including but not limited to transient references to QOL/PROs without specific analyses, nonoriginal research (eg, letters to the editor, commentary, or review articles), and QOL/PRO studies of other RT modalities with references to PBT. Of the 23 publications remaining, six were further eliminated because they lacked quantitative assessment, measured other non-QOL end points (eg, clinician-scored toxicities) from a QOL database, or evaluated objective measures alone (ie, without a prominent subjective component, such as intelligence quotient [IQ] only). Thus, 17 original investigations were 
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found to have sufficient focus and relevance to be incorporated into the systematic review.
Results
Skull Base, Brain, Head and and Neck, and Thorax Table 1 provides details of the studies included in this review. Srivastava et al. conducted a small (n ¼ 17) retrospective study of chordomas and chondrosarcomas using the EORTC-QLQ to evaluate QOL before and after treatment (27) . Although no end point past the immediate post-treatment period was evaluated, mean pre-and post-PBT scores were not statistically different, suggesting that QOL was not adversely affected by PBT. Although this and several studies to be discussed did not compare photon and PBT treatment, measuring of QOL/PRO trends over time in a single arm can serve as a starting point to facilitate more rigorous future comparisons.
A prospective study of 20 patients with low-grade gliomas (LGGs) treated with PBT was notable for assessing a diverse array of QOL measures (28) . With a median follow-up of 5.1 years, no declines were noted in executive function, processing speed, verbal/visual/working memory, or visuospatial and intelligence domains. Statistical improvements (per year) were seen in QOL scores for fatigue and visuospatial parameters. This study had notable limitations, including a relatively small and heterogeneous cohort comprising both primary (n ¼ 8) and recurrent (n ¼ 12) LGGs, as well as patients with prior symptomatology leading to PBT initiation. QOL for patients who progressed was not reported.
Investigators at MD Anderson Cancer Center reported a prospective QOL registry-based comparison of oropharyngeal cancer treated with definitive chemoradiation using intensitymodulated proton therapy (IMPT; n ¼ 35) or IMRT (n ¼ 46) (29) . The authors used the head and neck MDASI instrument and grouped PROs by time course (during RT, acute; three or fewer months from RT, subacute; more than three months from RT, chronic). IMPT was associated with improved PROs compared to IMRT, most notably in the subacute period (taste, appetite), and resulted in a lower proportion of patients with moderate-tosevere taste and mucus impairments. IMPT also improved overall PRO scores when collectively assessing the five most frequent symptoms (which varied between measurement periods). Along with the relatively short (median ¼ 7.7 months) followup, the data were confounded by the higher baseline QOL and lower doses delivered in the IMPT group. The study did not report stratification for performance status, smoking history, socioeconomic status, or p16 status.
A report from the same institution evaluated 82 locally advanced non-small cell lung cancer (NSCLC) patients treated with definitive chemoradiation using PBT (n ¼ 26), IMRT (n ¼ 34), or 3DCRT (n ¼ 22) (30) . The lung MDASI was utilized. All three groups displayed PRO declines during treatment; these persisted up to five weeks post-therapy in the photon cohort but not the PBT cohort. PBT was also associated with better scores in treatment-related pain and drowsiness. The multivariable analysis showed PBT to be independently associated with post-RT systemic symptoms, including pain. It is also noteworthy that patients in the PBT group receiving the highest RT doses (median ¼ 71 Gy relative biological effectiveness [GyRBE]) also had higher performance statuses. Differentiating based on tumor bulk and location (eg, central vs more peripheral) was also not addressed.
Breast
Breast cancer cosmesis is a PRO that is often graded using the Harvard four-point scale (excellent, good, fair, poor) ( Table 2) . Although clinical data on PBT for breast cancer are limited, two original studies of accelerated partial breast irradiation (APBI) met the inclusion criteria. The only comparative data were part of a phase I trial of PBT (n ¼ 19) and photon-based (n ¼ 79) APBI (31) . At median follow-up of 82.5 months, PBT displayed similar excellent late (seven-year) patient-reported cosmetic outcomes (P ¼ .95), although physician-reported cosmesis was statistically significantly worse for PBT patients (P ¼ .03). A unique feature of this study was the use of a patient satisfaction rating, which also displayed no statistical differences between groups at one, five, and seven years post-treatment. A notable limitation to this study was the utilization of only one PBT field treated per day and passively scattered PBT. No data were provided on skin doses received by each group.
Investigators at Loma Linda University performed a noncomparative prospective investigation of 100 breast cancer patients treated with PBT (32) . This differed from the previous report (31) in terms of dose (40 GyRBE delivered in 10 daily fractions, vs 32 GyRBE twice daily) (31), treatment of multiple fields per fraction, and prone setup with smaller total margins. At median follow-up of 60 months, the authors concluded that PBT resulted in appropriate cosmesis, with excellent or good results in at least 90% of patients at each measured time point (one, three, and five years).
Prostate
Complete details of the prostate cancer studies in this analysis are included in Table 3 . Talcott et al. performed a crosssectional analysis of 280 patients in the Proton Radiation Oncology Group 9509 trial, evaluating 19.8 vs 20.8 GyRBE of PBT boost treatment after 50.4 Gy photon therapy (33) . The PCSI scale was the primary PRO utilized, and the median follow-up was 9.4 years. The primary findings of no differences between arms (with lower cancer control concerns and regret in the high-dose cohort) led to a conclusion of no association between dose escalation and worse PROs. In addition to the shortcomings of a cross-sectional analysis using combined photon/PBT treatment, baseline symptoms were not assessed for comparison, which was a major confounding factor.
Gray et al. presented a pooled experience of prospectively collected PROs (using both EPIC and PCSI) in 371 patients treated with PBT (n ¼ 95), IMRT (n ¼ 153), or 3DCRT (n ¼ 123) (34) . Dosing in this study was heterogeneous and depended on the specific institution and treatment era; the final endpoint was relatively short at 24 months. At two to three months, all groups experienced decline in urinary obstruction/irritation scores. Bowel scores statistically significantly declined in both photon groups, whereas they only trended toward decline in the PBT group (P ¼ .06). Patients receiving IMRT reported statistically worse incontinence than those receiving PBT or 3DCRT. At 12 and 24 months, all groups had notable bowel PRO decline, with no clear differentiation between PROs in the PBT and photon groups. The authors concluded that PBT resulted in PRO declines similar to those with photon-based modalities.
A publication from the University of Florida prospectively collected PRO information on 1447 patients (n ¼ 1243 PBT, n ¼ 204 IMRT) (35) . The PBT patients were younger, less likely to receive androgen deprivation therapy, had smaller prostate (36) . The EPIC instrument was used, although at nonstandardized intervals. The main result of this noncomparative observational study was a clinically significant (generally defined as 50% of the standard deviation) decline in urinary and bowel subscale scores; whereas urinary function/bother and obstruction/irritation statistically normalized by six months, incontinence and bowel PRO declines persisted. However, there was no stratification for ADT as well as nonuniform duration of use.
A study from the Proton Collaborative Group prospectively treated 49 low-risk patients with hypofractionated PBT (38 GyRBE in five fractions) (37) . The group observed decreased urinary, bowel, and sexual EPIC scores at the latest time point of 24 months, along with worsened American Urological Association scores at 12 and 18 months. This represents the only eligible study on PBT-based stereotactic radiation therapy, but the results should not be generalized to the nonhypofractionated setting.
A phase II comparison of PBT with carbon ion RT (n ¼ 46 each) from the Heidelberg Ion Therapy Center evaluated a more modestly hypofractionated approach (66 GyRBE in 20 fractions) and was the only prostate PBT study to assess QOL (EORTC-QLQ), although at a shortened follow-up of up to six months post-treatment (38) . This study is also unique for the placement of a gel spacer prior to RT. The report detailed QOL parameters that initially declined but improved at six weeks and six months (this analysis did not compare by modality). Overall, the urinary and bowel QOL was higher in the carbon ion RT arm, although the authors concluded that QOL was comparable in both groups.
Two additional studies from the University of Florida experience were included because of assessment and stratification by prior transurethral resection of the prostate (TURP) and cryosurgery/high-intensity focused ultrasound (CS/HIFU) (39, 40) . In one study, 1289 patients were stratified into those with prior TURP (n ¼ 96) and those without (n ¼ 1193). This investigation (median follow-up ¼ 5.3 years) was important because it established that TURP was associated with worse initial PROs. However, differences in obstructive and bowel PROs remitted by one and two years, respectively. Incontinence and sexual PROs remained low at the three-year time period. Additionally, the TURP group was older, at higher risk (unknown receipt of pelvic nodal RT), and had greater ADT and 5a-reductase inhibitor usage. The second report described 21 patients treated with PBT following local recurrence after initial CS/HIFU. Based on scores at 12 months, all parameters were stable in the shorter term, except bowel scores, which were clinically lower. REVIEW neurobehavioral tests. QOL rose from the start to the end of PBT (in both craniospinal irradiation [CSI] and non-CSI patients), and less so thereafter to three years. Clinical factors associated with poorer QOL included baseline scores, posterior fossa location, receipt of CSI, and histology of germ cell or primitive neuroectodermal tumor. Associated treatment factors were receipt of chemotherapy and therapy with either PBT alone or trimodality therapy. Although factors associated with worse QOL at later end points were not explicitly assessed, the study provided a valuable framework for further inquiry. Two retrospective series from the Paul Scherrer Institute (using pencil-beam scanning PBT) were assessed. The first evaluated PedsQOL results in 15 patients with atypical teratoid/ rhabdoid tumor with a median 33-month follow-up (42) . The results were similar to those of Kuhlthau and colleagues (41) , chiefly that most QOL scores tended to increase as treatment progressed. This was also reflected in another study of rhabdomyosarcoma (43) , which included 93 patients, 34 of whom completed the questionnaire (patients younger than age five years were excluded). The scores were matched with those from a proxy "normal" population. The findings supported prior data: QOL improved in all domains starting at the two-month mark and continued to improve throughout the first year after therapy. The authors noted that at the two-year time point, most QOL domains were comparable to or higher than those in the proxy normal population.
Pediatric

Discussion
The major factors driving implementation and critical evaluation of PBT include relative potential toxicity reductions and improvements in post-treatment QOL decline. To that extent, this is the first systematic review comprehensively and critically reviewing QOL and PRO outcomes following PBT. These findings have notable implications for stakeholders, VBO, and PBT clinical trial design.
The available evidence suggests that PBT provides favorable QOL/PRO profiles for select brain, head/neck, lung, and pediatric cancers. A complete discussion of analogous photon studies is beyond the scope of this paper, and substantial heterogeneity characterizes QOL/PRO studies. However, select data from this review will be briefly discussed. As compared with the findings by Shih et al. (28) , QOL assessment of a phase III LGG trial of photon RT (without chemotherapy) displayed steady declines in both QOL and mental state questionnaire results (44) . Regarding head/neck cancers, for which QOL studies are especially subject to bias from patient and treatment parameters, there were notable QOL declines with more aggressive therapy, which also associated with a greater symptom burden (45) . To this extent, the finding of generally lower toxicities for PBT than for photon therapy could be noteworthy and supports the aforementioned (and other) data from MD Anderson indicating lower rates of feeding tube requirements with IMPT (46, 47) . In locally advanced NSCLC, the results from Wang et al. (30) are consistent in the context of QOL data from a recent phase III dose escalation study showing notable QOL declines in both arms (more so in the high-dose arm) (48) . Perhaps most notably, the fact that higher conformality of IMRT was associated with fewer functional assessment score declines than 3DCRT could suggest favorable results for IMPT in subsequent comparisons with IMRT.
For pediatric malignancies, QOL results were relatively corroborative, with all three reports suggesting QOL improvements (and not declines) during and after PBT. Although the gradual relief of initial anxiety plays a clear role in these results (highlighting the importance of actively involving child life specialists and/or psychologists), they should also be considered in the context of photon data demonstrating decreases in QOL steadily after RT (49, 50) . In addition, a retrospective comparison (51) of post-therapy IQ in PBT and photon RT has demonstrated greater decline with photon RT, although the rate of decline was not different between groups.
Post-PBT QOL/PRO results for breast and prostate cancers were more modest. There was only one comparative study in breast cancer showing no differences between PBT and photons, which is consistent with prospective data reporting comparable pre-and post-RT QOL with photon RT (52) . However, the fact that PBT can be utilized in the APBI setting is important because a recent secondary analysis of phase III data indicated that photon APBI results in higher QOL than conventionally fractionated photon whole-breast RT (53) . Prostate cancer is currently the focus of the greatest amount of QOL/PRO data; results for PBT analyzed here in are consistent with findings of retrospectively (54, 55) and prospectively collected (56) data displaying no differences in toxicities between PBT and IMRT. However, the finding that stereotactic RT (acknowledging the impact of various dosing regimens) does not produce worse QOL than moderate hypofractionation could be implemented to alter QOL outcomes in future analyses (57) .
The main conclusions of this review roughly mirror those of the CE of PBT (25) and further illustrate the connection-and, to some extent, interdependence-between QOL and CE. It has been proposed that, based on limited evidence, PBT is costeffective for pediatric brain neoplasms, locally advanced NSCLC, and some head and neck cancers; it was not costeffective for prostate cancer and unselected breast cancer cases. Indeed, although these and future QOL/PRO findings will substantially impact the results of future CE analyses, these investigations must utilize QOL data much more frequently than at present (25) . More important is the identification of the best methods to integrate QOL into CE studies by relating QOL data to utility values and numeric relationships with cost. This will undoubtedly require major extrapolation (clearly already the basis for CE studies), but the real importance of further data will be when averaging the values from multiple QOL studies instead of complete reliance on single investigations (thus decreasing bias). In addition, QOL (and CE) data are urgently needed for neoplasms for which PBT could offer intuitive advantages (eg, postoperative toxicity/complication reduction in esophageal cancer) (16) .
One major impact of these and other QOL data on health policy and VBO can be seen in statements made by the American Society of Clinical Oncology (ASCO) Value in Cancer Care Task Force (58) . This group initially constructed a quantitative "net health benefit" score associated with a particular intervention, referring to balancing its potential "clinical benefits" with costs. When performing revisions to the initial framework, the Task Force noted a prominent deficiency in both PRO and QOL information. However, the presence of available supportive QOL/PRO information now results in "bonus points" assigned to the net health benefit score. This has been a major step in directly integrating QOL/PRO data with the quantitative metrics of CE. The findings of this systematic review will likely be of interest not only to the Task Force and ASCO's Quality Oncology Practice Initiative (59) but also to stakeholders using similar metrics to assess the "net health benefits" of PBT.
These findings also have implications for ongoing clinical trials (60) . As evidence of the increased focus of QOL in these The primary endpoints of most trials are toxicity related, which highlights the need to actively associate these toxicity endpoints with QOL endpoints. Doing so will not only enhance the importance of potential toxicity reductions afforded by PBT for QOL but also serve to more directly integrate QOL metrics into future CE studies. We also encourage clinical trials to include high-quality, validated PRO/QOL assessments prospectively in the most homogeneous populations possible. Emphasis should be placed on global health-related QOL, which provides a unique and important parameter that could be most indicative of PBT efficacy (analogous to the primacy of overall survival as a primary endpoint in many trials). Trials should aim to identify as many sources of potential QOL/PRO bias as possible when performing initial data collection. Many of the studies discussed in this review did not stratify for socioeconomic, marital, employment, or comorbidity status. Organspecific parameters are equally important, as these will have a major impact on QOL, and consideration should be given to factors like smoking history, prostate volume (only two analyzed studies reported this), prior surgeries, and relevant medications (per Lee et al. [35] ). Disease-specific factors are also needed, including but not limited to genomic/molecular data, tumor location (eg, at a high-risk anatomic area), and disease volume. Finally, the majority of studies did not conduct multivariable adjustment of QOL based on treatment modality, and this should also be performed whenever possible. Lastly, recent advances in PBT delivery techniques, such as at the advent of IMPT and volumetric image guidance, could substantially impact the results of future QOL analyses. For instance, it is important to note that comparison of forwardplanned passively scattered PBT (which comprised the dominant technique in the studies discussed herein) is most analogous to photon 3D-CRT. IMRT would more appropriately be compared with inverse-planned IMPT (which, owing to its newer implementation in clinical practice, has much more limited QOL/PRO data available to date. Therefore, existing literature comparing advanced photon techniques with firstgeneration proton techniques might be inherently biased against proton therapy.
There are also biases regarding the learning curve of new technologies such as PBT as compared to more established photon techniques such as IMRT. Additionally, in nonrandomized trials, there are unavoidable selection biases regarding the use of protons vs photons to treat a given patient, such as proximity to organs at risk or ease/difficulty in meeting dose constraints with protons vs photons. Furthermore, in both randomized and nonrandomized trials, insurance status (eg, Medicare is more likely to pay for elderly patients' PBT, vs other commercial insurances less likely to pay in the non-Medicare population) may play a factor in who receives which type of radiotherapy modality, and this may also have served to bias existing studies reporting on QOL/PROs.
Limitations of this work, similar to CE analyses, are that there are no "perfectly conducted" QOL/PRO studies. These parameters are inherently subjective and are influenced by numerous factors, including inherent psychosocial, behavioral, and cultural attitudes. It is impossible for investigations to account for all of these variables, acknowledging that confounding factors will always be present (at the very least, potentially biased in PBT patient selection regarding those with the means to travel longer distances to PBT facilities) (Tables 1-4) . Rather, also similar to CE work, the goal of a QOL/PRO investigation is to provide a rough comparison between groups (or observation of a cohort) so that, ideally, further work can be corroborated by additional research. QOL/PRO data are thus important to recognize as constituting a dynamically changing entity that can be substantially influenced by the quality and volume of further additional data (including patient selection) as they are published. Herein, although the overall quality and quantity of data available on QOL and PBT remain relatively low, thus permitting few robust conclusions, there are salient "lessons to be learned" that can allow for sharper and more insightful interpretation of QOL/PRO analyses of active and planned clinical trials.
Taken together, the lessons for ongoing clinical trials involve performing high-quality, thorough QOL/PRO evaluations. Doing so may allow for delineation of patient subpopulations that proportionally receive greater QOL (and CE) benefits (as QOL is not a binary term); moreover, it will increase the applicability, impact, validity, and reliability of the data on both future CE analyses and VBO as a whole. This is critical to consider, especially in an ever-changing medico-economic climate.
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